Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Average Target Price from Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has been given an average rating of “Hold” by the seven ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.92.

CDLX has been the topic of several research analyst reports. Evercore ISI initiated coverage on shares of Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price on the stock. Northland Securities lowered shares of Cardlytics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $7.00 to $5.00 in a report on Friday, August 16th. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Finally, Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th.

Insiders Place Their Bets

In other news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This represents a 11.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alexis Desieno sold 25,118 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the sale, the chief financial officer now directly owns 116,481 shares in the company, valued at $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,691 shares of company stock worth $237,767. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Cardlytics

Several large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock valued at $432,000 after acquiring an additional 1,774 shares during the period. Canton Hathaway LLC grew its position in shares of Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock worth $37,000 after buying an additional 2,200 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Cardlytics by 15.4% during the second quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock worth $1,116,000 after buying an additional 18,179 shares during the last quarter. Ingalls & Snyder LLC lifted its holdings in Cardlytics by 106.0% in the second quarter. Ingalls & Snyder LLC now owns 32,464 shares of the company’s stock valued at $267,000 after buying an additional 16,708 shares during the period. Finally, Quest Partners LLC boosted its stake in Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after acquiring an additional 11,061 shares during the last quarter. Institutional investors own 68.10% of the company’s stock.

Cardlytics Stock Up 4.2 %

Shares of NASDAQ:CDLX opened at $3.73 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The company has a market capitalization of $189.56 million, a P/E ratio of -0.61 and a beta of 1.53. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52. The stock’s fifty day simple moving average is $3.90 and its 200-day simple moving average is $5.44.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.18. The company had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm’s revenue for the quarter was down 15.1% compared to the same quarter last year. During the same period last year, the company earned ($0.26) EPS. As a group, equities research analysts forecast that Cardlytics will post -1.52 earnings per share for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.